MeSH tree: E01.789.800
For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according ...
Jul 2, 2026
0
3
Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically ...
Jul 1, 2026
0
5
A large real-world clinical trial has found that a generative AI-powered support tool used to support frontline clinicians was safe and improved the quality of clinical decision-making, but did not significantly change short-term ...
Jun 26, 2026
0
9
Global health policymakers should focus on the way entire health care systems work together, argue researchers in new findings. Improving one element does not always create better outcomes if the wider system is not ready.
Jun 21, 2026
0
3
The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma ...
Jun 19, 2026
0
8
Physicians and researchers at the Netherlands Cancer Institute have developed an AI model that outperforms physicians in evaluating treatment response in pleural mesothelioma. Far more accurate than the current international ...
Jun 17, 2026
0
6
Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with standard-of-care ...
Jun 15, 2026
0
4
A new Northwestern Medicine study suggests that a simple blood test could help identify which patients with head and neck cancer will be most likely to benefit from immunotherapy, according to a study published in the Journal ...
Jun 8, 2026
0
4
Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival ...
Jun 2, 2026
0
29
A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare ...
Jun 1, 2026
0
6
